Quarterly report pursuant to Section 13 or 15(d)

Share-based Payments

v3.19.2
Share-based Payments
6 Months Ended
Jun. 30, 2019
Share-based Payment Arrangement [Abstract]  
Share-based Payments

Note 6 - Share-based Payments

 

Equity incentive Plans

 

2013 Stock Incentive Plan

 

On January 23, 2014, the Company adopted the 2013 Stock Incentive Plan (“2013 Plan”). The 2013 Plan was amended by the Board on January 9, 2015 and September 30, 2016, and such amendments were ratified by shareholders on December 7, 2018. The 2013 Plan provides for the issuance of up to 103,750 shares of the Company’s common stock. As of June 30, 2019, grants of restricted stock and options to purchase 71,590 shares of Common Stock have been issued pursuant to the 2013 Plan, and 32,160 shares of Common Stock remain available for issuance.

 

2017 Stock Incentive Plan

 

On August 7, 2017, the shareholders approved and the Company adopted the 2017 Stock Incentive Plan (“2017 Plan”). The 2017 Plan provides for the issuance of up to 168,750 shares of the Company’s common stock. As of June 30, 2019, grants of restricted stock and options to purchase 62,282 shares of Common Stock have been issued pursuant to the 2017 Plan, and 106,468 shares of Common Stock remain available for issuance.

 

2018 Stock Incentive Plan

 

On December 7, 2018, the shareholders approved and the Company adopted the 2018 Stock Incentive Plan (“2018 Plan”). The 2018 Plan provides for the issuance of up to 1,875,000 shares of the Company’s common stock. As of June 30, 2019, grants of RSUs to purchase 374,481 shares of Common Stock have been issued pursuant to the 2018 Plan, and 1,500,519 shares of Common Stock remain available for issuance.

 

Stock Options

 

The following table summarizes the option activities for the six months ended June 30, 2019:

 

    Number of Shares     Weighted Average Exercise Price     Weighted Average Grant Date Fair Value     Weighted Average Remaining Contractual Term (years)     Aggregate
Intrinsic Value
 
Balance at December 31, 2018     10,502     $ 30.41     $ 17.42       1.43     $           -  
Granted     -       -       -       -       -  
Exercised     -       -       -       -       -  
Forfeited     (6,438 )     33.79       23.72       0.58       -  
Canceled/Expired     -       -       -       -       -  
Balance at June 30, 2019     4,064     $ 25.04     $ 7.46       1.50     $ -  
Exercisable as of June 30, 2019     4,064     $ 25.04     $ 7.46       1.50     $ -  

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.45 for the Company’s common shares on June 30, 2019. As the closing stock price on June 30, 2019 is lower than the exercise price, there is no intrinsic value to disclose.

 

As of June 30, 2019, all of the Company’s outstanding stock options were fully vested and exercisable.

 

During the three months ended June 30, 2019 and 2018, the Company incurred stock option expenses totaling $0 and $2,742, respectively and $0 and $5,454 for the six months ended June 30, 2019 and 2018, respectively.

 

Restricted Stock Units

 

On March 29, 2019, the Compensation Committee of the Board of Directors approved the grant of 124,827 Restricted Stock Units (“RSU”) to each of the three directors. Each RSU had a grant date fair value of $0.97 which shall be amortized on a straight-line basis over the vesting period into administrative expenses within the Condensed Consolidated Statement of Operations and Comprehensive Loss. Such RSUs were granted under the 2018 Plan, and shall vest on January 1, 2020, with vesting accelerated upon a change of control. Upon vesting, such RSUs are settled with the issuance of common stock, including on a net of tax basis, at the discretion of the holder.

 

At June 30, 2019, the unamortized value of the RSU’s was $240,863. The unamortized amount will be expensed over the remaining period of six months. A summary of activity related to RSUs for the six months ended June 30, 2019 is presented below:

 

    Number of RSUs     Weighted Average Grant
Date Fair Value
 
Balance at December 31, 2018     -     $ -  
Granted     374,481     $ 0.97  
Exercised     -       -  
Forfeited     -       -  
Canceled/Expired     -       -  
Balance at June 30, 2019     374,481     $ 0.97  
Exercisable as of June 30, 2019     -       -  

 

During the three and six months ended June 30, 2019, the Company incurred RSU expense of $118,478 and $122,384, respectively.

 

Stock Warrants

 

The table below summarizes the warrant activity for the period ended June 30, 2019:

 

    Number of Warrants     Weighted Average
Exercise Price
    Average Remaining Contractual Term (years)     Aggregate
Intrinsic Value
 
Balance at December 31, 2018     2,110,737     $ 3.10       4.21     $                 -  
Granted     -       -       -       -  
Exercised     -       -       -       -  
Forfeited     -       -       -       -  
Canceled/Expired     -       -       -       -  
Balance at June 30, 2019     2,110,737     $ 3.10       3.71     $ -  
Exercisable as of June 30, 2019     2,110,737     $ 3.10       3.71     $ -  

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.45 for the Company’s common shares on June 30, 2019. All warrants were vested on date of grant.